We’ve previously written about Allergan’s First Amendment challenge to the FDA’s regulations relating to off-label promotion (here(last of four parts), here, and here), but in the grand tradition of the First Amendment, the war of words is escalating, mud is being slung, and court filings are name-dropping Trojan priests – but more on that later.

The past month has been busy, with the government filing its “Motion (more…)